Galecto Biotech Ab

Avexxin As

Apoglyx Ab

Thomas Brimert

Ulf Nilsson

Hakon Leffler

Fredrik Zetterberg

Richard Johnsson

Johan Evenäs

Berit Johansen

George Kokotos

Inger-Reidun Aukrust

Anders Pedersen

Marcel Sandberg

Geir Kildahl-Andersen

Kildahl-Andersen Geir

Joakim Larsson

Marcel Sanderberg

Hans Schambye

Klaus Dreisch

Priya Verma

Michael Rützler

An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

Galactoside inhibitor of galectins

A compound of formula (I') wherein Ris H, Calkyl, &#x2014;(CH)COOH, &#x2014;(CH)COOCalkyl, &#x2014;(CH)CONH, &#x2014;(CH)CONHCalkyl, &#x2014;(CH)CON(Calkyl), Ris as defined for R; or and Rtaken together with the atoms joining them can form a 6-membered aromatic or non aromatic, saturated or unsaturated, carbocyclic or heteroatom containing (e.g. O, N or S containing) ring optionally substituted by up to 4 groups R; each Ris defined as for Ror is oxo; Ris Calkyl Ar is a Caryl group, wherein the aryl group may be optionally substituted (preferably in the meta or para position relative to O) with one or more Rgroups; each Ris halo, OH, CN, nitro, NH, NHCalkyl, N(Calkyl), haloCalkyl, Caryl group, Carylalkyl, a Calkyl group, C-mono or multiply unsaturated alkenyl group, OCalkyl group, SCalkyl group &#x2014;OCalkyl-O&#x2014;Calkyl, &#x2014;Calkyl-O&#x2014;Calkyl, &#x2014;OC-mono or multiply unsaturated alkenyl group, OAr, O(CH)Ar, SAror S(CH)Ar; wherein Aris phenyl, optionally substituted with one or more of halo, trihalomethyl, C-alkoxy, or Calkyl; each q is 1 to 3, preferably 1; each p is 0 to 3; or a salt, ester, solvate, N-oxide, or prodrug thereof. 

2-oxothiatole compounds having activity as cPLAinhibitors for the treatment of inflammatory disorders and hyperproliferative disorders

The present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore, the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

1,1 '-sulfanediyl-di-beta-D-galactopyranosides as inhibitors of galectins

An Embodiment of the invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.

2-oxothiatole compounds having activity as CPLA2 inhibitors for the treatment of inflammatory disorders and hyperproliferative disorders

Disclosed are compounds, pharmaceutical compositions and methods for modulating aquaporin 9.

Derivatives of 2-(1,2,4-triazol-3-ylsulfanyl)-N-1,3,4-thiadiazol-2-yl acetamide which are useful for the treatment of inter alia diabetes

Growing community of inventors

Blentarp, Sweden

Thomas Brimert